Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

Depression and Anxiety

Volumn 26, Issue 1, 2009, Pages 83-97

  Mauskopf, Josephine A ^a   Simon, Gregory E ^b   Kalsekar, Anupama ^c   Nimsch, Christian ^a   Dunayevich, Eduardo ^c   Cameron, Ann ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b Center for Health Studies   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Cost; Nonresponse; Partial response; Quality of life; Remission

Indexed keywords

ARTICLE; CONTROLLED STUDY; FUNCTIONAL STATUS; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; MEDICAL INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION;

ACTIVITIES OF DAILY LIVING; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DISABILITY EVALUATION; HEALTH CARE COSTS; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT FAILURE;

EID: 58549120192     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20505     Document Type: Article

References (81)

1. World Health Organization (WHO). The World Health Report: 2001: Mental Health: New Understanding, New Hope, 2001. Available at: http://www.who.int/whr/ en/. Accessed December 15, 2005.
2. Alonso J, Angermeyer AJ, Bernert S et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;420:21-27.
3. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005;62:1097-1106.
4. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbid-ity Survey Replications (NCS-R). J Am Med Assoc 2003;289: 3095-3105.
5. Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-1475.
6. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003;183:514-519.
7. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry 1995;52:850-856.
8. Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. J Am Med Assoc 2002;287:203-209.
9. Patten SB. Progress against major depression in Canada. Can J Psychiatry 2002;47:775-780.
10. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;9:179-200.
11. Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999;21:296-308.
12. Mulrow CD, Williams JW, Chiquette E et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000;108:54-64.
13. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selected serotonin reuptake inhibitors or placebo. J Clin Psychiatry 2001;62:869-877.
14. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
15. Hirschfeld RM, Vornick LA. New antidepressants: review of efficacy and safety of escitalopram and duloxetine. J Clin Psychiatry 2004;65:46-52.
16. Bondolfi G, Aubry JM, Golaz M et al. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly 2006;136:78-85.
17. Simon GE, Chisholm D, Treglia M, Bushnell D, the LIDO Group. Course of depression, health services costs, and work productivity in an international primary care study. Gen Hosp Psychiatry 2002;24:328-335.
18. Fleck MP, Simon G, Hermann H, Bushnell D, Martin M. Major depression and its correlates in primary care settings in 6 countries: a 9-month follow-up study. Br JPsychiatry 2005;186:41-47.
19. Simon GE, Revicki D, Heiligenstein J et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-162.
20. Limosin F, Loze JY, Zylberman-Bouhassira M, Schmidt ME, Perrin E, Rouillon F. The course of depressive illness in general practice. Can J Psychiatry 2004;49:119-123.
21. Cuffel BJ, Azocar F, Tomlin M, Greenfield SF, Busch AB, Croghan TW. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed care practice. J Clin Psychiatry 2003;64:397-402.
22. Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-142.
23. Rush A, Trivedi M, Wisniewski S et al. Acute and longer-term outcomes in depressed outpatients who required one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917.
24. Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG. Cost-of-illness studies of depression: a systematic review. J Affect Disord 2007;98:29-43.
25. Berto P, d'llerio D, Ruffo P, Di Virgilio R, Rizzo F. Depression: cost of illness studies in the international literature, a review. J Ment Health Policy Econ 2000;3:3-10.
26. Driscoll HC, Karp JF, Dew MA, Reynolds CF. Getting better, getting well: understanding and managing partial and non-response to pharmacologic treatment of non-psychotic major depression in old age. Drugs Aging 2007;24: 801-814.
27. Furukawa TA, Cipriani A, Barbui C, Geddes JR. Long-term treatment of depression with anti-depressants : a systematic narrative review. Can J Psychiatry 2007;52:545-552.
28. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005;255:387-400.
29. Hirschfeld RM, Montgomery SA, Aguglia E et al. Partial response and non-response to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002;63: 826-837.
30. Corruble E, Guelfi JD. Does increasing dose improve efficacy in patients with poor antidepressant response: a review. Acta Psychiatr Scand 2000;101:343-348.
31. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 2005;84:1-13.
32. Pirraglia PA, Rosen AB, Hermann RC, Olchanski NV, Neumann P. Cost-utility analysis studies of depression management: a systematic review. Am J Psychiatry 2004;161:2155-2162.
33. Barbui C, Percudani M, Hotopf M. Economic evaluation of antidepressive agents: a systematic critique of experimental and observational studies. JClin Psychopharmacol 2003;23:145-154.
34. Simon GE. Evidence review: efficacy and effectiveness of antidepressant treatment in primary care. Gen Hosp Psychiatry 2002;24:213-224.
35. Panzarino PJ, Nash DB. Cost-effective treatment of depression with selective serotonic reuptake inhibitors. Am J Manag Care 2001;7:173-184.
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
37. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
38. Nierenberg AA, De Cecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment resistant depression. J Clin Psychiatry 2001;62:5-9.
39. Thase ME. Introduction: defining remission in patients treated with antidepressants. J Clin Psychiatry 1999;60:3-6.
40. Russell JM, Hawkins K, Ozminkowski RJ et al. The cost consequences oftreatment-resistant depression. JClinPsychiatry 2004;65:341-347.
41. Petersen T, Papakostas GI, Posternak MA et al. Empirical testing of two methods for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005;25:336-341.
42. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60:29-34.
43. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry 1999;60:7-11.
44. Wisniewski SR, Rush AJ, Bryan C et al. Comparison ofquality of life measures in a depressed population. J Nerv Ment Dis 2007;195:219-225.
45. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
46. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski S. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-459.
47. Miller IW, Keitner GI, Schatzberg AF et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-619.
48. Russell JM, Koran LM, Rush J et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 2001;13:18-27.
49. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction scale: a new measure. Psychopharma-col Bull 1993;29:321-326.
50. Doraiswamy PM, Khan ZM, Donahue RM, Richard NE. Quality of life in geriatric depression: a comparison of remitters, partial responders and nonresponders. Am J Geriatr Psychiatry 2001;9:423-428.
51. Doraiswamy PM, Khan ZM, Donahue RM, Richard NE. The spectrum of quality-of-life impairments in recurrent geriatric depression. J Gerontol A Biol Sci Med Sci 2002;57:M134-M137.
52. McKenna SP, Hunt SM. A new measure of quality of life in depression: testing the reliability and construct validity of the QLDS. Health Policy 1992;22:321-330.
53. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992;22: 307-319.
54. Weissman MM, Bolliwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976;33:1111-1115.
55. Ware Jr JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36) I: conceptual framework and item selection. Med Care 1992;30:473-483.
56. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004;164:1197-1204.
57. Papakostas GI, Petersen T, Denninger JW et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004;24:507-511.
58. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592.
59. Sapin C, Fantino B, Nowicki M, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004;2:20.
60. Pyne JM, Sieber WJ, David K, Kaplan RM, Rapaport MH, Williams DK. Use of quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients. J Affect Disord 2003;76:237-247.
61. Lenert LA, Sherbourne CD, Sugar C, Wells KB. Estimation of utilities for the effects of depression from the SF-12. Med Care 2000;38:763-770.
62. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998;48:25-36.
63. Sobocki P, Ekman M, Agren H et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60:791-798.
64. Pyne JM, Tripathi S, Williams K, Fortney J. Depression-free day to utility-weighted score: is it valid? Med Care 2007;45:357-362.
65. Gunther OH, Roick C, Angermeyer MC, Konig HH. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord 2008;105:81-91.
66. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. J Am Med Assoc 2003;289:3135-3144.
67. Pearson SD, Katzelnick DJ, Simon GE, Manning WG, Helstad CP, Henk HJ. Depression among high utilizers of medical care. J Gen Intern Med 1999;14:461-468.
68. Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002;63:717-726.
69. Crown WH, Finkelstein S, Berndt ER et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963-971.
70. Hawthorne G, Cheok F, GoldneyR, Fisher L. The excess cost of depression in South Australia; a population based study. Aust N Z J Psychiatry 2003;37:362-373.
71. Tranter R, O'Donovan C, Chandarana P, Kennedy S. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27:241-247.
72. McIntyre RS, Muller A, Mancini DA, Silver ES. What to do if an initial antidepressant fails? Can Fam Physician 2003;49: 449-457.
73. Sherbourne C, Schoenbaum M, Wells KB, Croghan TW. Characteristics, treatment patterns, and outcomes of persistent depression despite treatment in primary care. Gen Hosp Psychiatry 2004;26:106-114.
74. Trivedi MH, Rush AJ, Wisniewski SR et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry 2006;67:185-195.
75. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004;19:813-818.
76. Lustberg L, Reynolds CF. Depression and insomnia: questions of cause and effect. Sleep Med Rev 2000;4:253-262.
77. Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/ norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacol 2002;17:273-280.
78. Flint AJ, Rifat SL. Two-year outcome of elderly patients with anxious depression. Psychiatry Res 1997;66:23-31.
79. Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptoms specific? J Clin Psychiatry 2003;64:516-523.
80. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006;163:101-108.
81. Robinson RL, Long SR, Chang S et al. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims. J Manag Care Pharm 2006;12:43-54.